Table 2 Baseline characteristics of patients in the development and validation cohorts
Development data set ( n =170) | Validation data set ( n =266) | ||||||
|---|---|---|---|---|---|---|---|
Median OS | n | (%) | Median OS | n | (%) | P -value | |
Sex | 0.891 | ||||||
Female | 11.6 | 45 | (27) | 19.1 | 72 | (27) | |
Male | 22.4 | 125 | (73) | 29.3 | 194 | (73) | |
Nephrectomy | <0.001 | ||||||
No | 7.9 | 37 | (22) | 10.6 | 5 | (2) | |
Yes | 22.3 | 133 | (78) | 26.5 | 261 | (98) | |
Previous IFNa | <0.001 | ||||||
No | 19.4 | 154 | (91) | 31.7 | 148 | (56) | |
Yes | 22.3 | 16 | (9) | 22.2 | 118 | (44) | |
Time from initial diagnosis to sunitinib therapy | <0.001 | ||||||
⩽12 months | 14.2 | 90 | (53) | 21 | 90 | (34) | |
>12 months | 33.3 | 80 | (47) | 28.8 | 176 | (66) | |
Histology | <0.001 | ||||||
Clear Cell | 19.4 | 149 | (87) | 26.9 | 256 | (96) | |
Other | 19.8 | 20 | (12) | 7.9 | 10 | (4) | |
Missing | - | 1 | (1) | 0 | (0) | ||
Tumour grade | 0.199 | ||||||
I | NR | 3 | (2) | 29.3 | 2 | (1) | |
II | 28.8 | 44 | (26) | 40.2 | 53 | (20) | |
III | 16.4 | 62 | (36) | 29 | 113 | (43) | |
IV | 17.2 | 27 | (16) | 17.3 | 55 | (21) | |
Missing | 34 | (20) | 43 | (16) | |||
Neutrophils status | 0.615 | ||||||
⩽5000 | 24.7 | 66 | (39) | 34.4 | 130 | (49) | |
>5000 | 15.1 | 64 | (38) | 18.8 | 113 | (43) | |
Missing | 40 | (23) | 23 | (9) | |||
Platelets status | 0.595 | ||||||
⩽400 | 22.3 | 118 | (69) | 29 | 217 | (82) | |
>400 | 11.2 | 27 | (16) | 13.7 | 43 | (16) | |
Missing | 25 | (15) | 6 | (2) | |||
Karnofsky performance status | 0.086 | ||||||
0 | 36.7 | 96 | (57) | 37.2 | 160 | (60) | |
1 | 16.2 | 53 | (31) | 18.6 | 91 | (34) | |
2 | 6.4 | 16 | (9) | 6 | 10 | (4) | |
3 | 3.4 | 5 | (3) | 13.6 | 5 | (2) | |
Total number of metastatic sites | <0.001 | ||||||
0–2 | 29 | 123 | (72) | 33 | 131 | (49) | |
>2 | 7.9 | 47 | (28) | 18.8 | 135 | (51) | |
LDH | <0.001 | ||||||
Normal | 29.2 | 74 | (44) | 26.1 | 214 | (81) | |
Abnormal | 13.9 | 50 | (29) | 23.6 | 35 | (13) | |
Missing | 46 | (27) | 17 | (6) | |||
Calcium | 0.537 | ||||||
⩽10 | 20.8 | 102 | (60) | 24.9 | 214 | (81) | |
>10 | 9.8 | 18 | (10) | 26.9 | 31 | (12) | |
Missing | 50 | (30) | 21 | (8) | |||
Haemoglobin | 0.309 | ||||||
⩽13 for males, ⩽11.5 for females | 12 | 69 | (41) | 17.9 | 108 | (41) | |
>13 for males, >11.5 for females | 29 | 77 | (45) | 30 | 149 | (56) | |
Missing | 24 | (14) | 9 | (3) | |||
Heng’s risk classification | <0.001 | ||||||
Favourable | 37.4 | 16 | (9) | 40.2 | 53 | (20) | |
Intermediate | 28.8 | 57 | (34) | 21 | 126 | (47) | |
Poor | 11.2 | 32 | (19) | 13.6 | 48 | (18) | |
Missing | 65 | (38) | 39 | (15) | |||
Motzer’s risk classification | <0.001 | ||||||
Favourable | NR | 16 | (9) | 38.1 | 59 | (22) | |
Intermediate | 29.2 | 61 | (36) | 21 | 134 | (50) | |
Poor | 11.6 | 37 | (22) | 13.6 | 44 | (17) | |
Missing | 56 | (33) | 29 | (11) | |||
